Owens & Minor (NYSE:OMI) Updates FY 2025 Earnings Guidance

Owens & Minor (NYSE:OMI) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided earnings per share guidance of 1.600-1.850 for the period, compared to the consensus earnings per share estimate of 1.790. The company issued revenue guidance of $10.9 billion-$11.2 billion, compared to the consensus revenue estimate of $11.0 billion. Owens & Minor also updated its FY25 guidance to $1.60-1.85 EPS.

Owens & Minor Trading Up 38.7 %

NYSE OMI opened at $9.56 on Friday. Owens & Minor has a fifty-two week low of $6.07 and a fifty-two week high of $28.35. The company has a debt-to-equity ratio of 2.11, a quick ratio of 0.45 and a current ratio of 1.09. The stock has a 50 day simple moving average of $11.51 and a two-hundred day simple moving average of $13.26. The stock has a market cap of $736.78 million, a P/E ratio of -14.70, a price-to-earnings-growth ratio of 0.20 and a beta of 0.48.

Owens & Minor (NYSE:OMI) last released its quarterly earnings data on Friday, February 28th. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of $0.53 by $0.02. Owens & Minor had a positive return on equity of 14.60% and a negative net margin of 0.46%. The business had revenue of $2.70 billion during the quarter, compared to analysts’ expectations of $2.68 billion. During the same quarter last year, the business posted $0.69 EPS. The business’s revenue was up 1.5% on a year-over-year basis. On average, analysts forecast that Owens & Minor will post 1.51 earnings per share for the current year.

Owens & Minor declared that its board has approved a share buyback plan on Friday, February 28th that permits the company to repurchase $100.00 million in shares. This repurchase authorization permits the company to buy up to 13.6% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s leadership believes its stock is undervalued.

Analysts Set New Price Targets

OMI has been the subject of a number of research analyst reports. UBS Group lowered their target price on Owens & Minor from $25.00 to $13.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. Robert W. Baird lowered their target price on Owens & Minor from $14.00 to $10.00 and set a “neutral” rating for the company in a research note on Tuesday. Barclays lowered their target price on Owens & Minor from $18.00 to $14.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 5th. Finally, Citigroup lowered their target price on Owens & Minor from $21.00 to $18.50 and set a “buy” rating for the company in a research note on Tuesday, November 5th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Owens & Minor currently has a consensus rating of “Hold” and an average price target of $14.92.

Owens & Minor Company Profile

Owens & Minor, Inc is a healthcare solutions company, which engages in the product manufacturing and delivery, home health supply, and perioperative services to support care through the hospital and into the home. It operates through the Products and Healthcare Services, and Patient Direct segments.